AstraZeneca buys Almirall lung drugs for up to $2.1 billion

startup_marketing

(Reuters) – AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall’s lung drugs.

The British drugmaker, which resisted a $118 billion takeover attempt by Pfizer in May, said it would pay an initial $875 million and up to $1.22 billion more if the drugs meet development and sales targets.

Continue reading